Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06066645 · ClinicalTrials.gov registry record · Phase 3
Travoprost Intraocular Implant + iStent Infinite vs. iStent Infinite Alone
A Phase 3 study of Glaucoma Open-Angle, sponsored by Glaukos Corporation.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 230
- Enrollment target
- 1
- Study location
NCT06066645 is a Phase 3 study of Glaucoma Open-Angle that is actively recruiting participants, run by Glaukos Corporation. The registered enrollment target is 230 participants, above the 155-participant average among 22 other Glaucoma Open-Angle trials with a reported enrollment target (48% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06066645, a Phase 3 study of Glaucoma Open-Angle, is actively recruiting participants, sponsored by Glaukos Corporation.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 230 participants
- Enrollment target
- 1
- Study location
Study Summary
Adult subjects with elevated intraocular pressure who have successfully undergone placement of iStent infinite trabecular bypass system will be randomized to receive a travoprost intraocular implant or receive a sham procedure and be followed for 12 months.
Conditions Studied
Interventions
- DRUG Travoprost Intraocular Implant
- OTHER Sham procedure 1
- DEVICE iStent infinite
- OTHER Sham procedure 2
Study Locations (1)
Colorado
- Glaukos Clinical Study Site - Colorado Springs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2023-09-14 |
| Est. Completion | 2028-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06066645
The ClinicalTrials.gov registry entry for NCT06066645 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 230 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 155-participant average among 22 other Glaucoma Open-Angle trials with a reported enrollment target (48% higher). The listed sponsor is Glaukos Corporation, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glaucoma Open-Angle appearing as the primary indexed condition, and to 4 interventions - of which Travoprost Intraocular Implant is the first listed.
NCT06066645 reports 1 study location spanning 1 distinct geographic area - top geographies include Colorado.
Frequently Asked Questions
What is clinical trial NCT06066645 about?
NCT06066645 is a clinical study titled "Travoprost Intraocular Implant + iStent Infinite vs. iStent Infinite Alone". Adult subjects with elevated intraocular pressure who have successfully undergone placement of iStent infinite trabecular bypass system will be randomized to receive a travoprost intraocular implant or receive a sham procedure and be followed for 12 months.
What is the current status of trial NCT06066645?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 230 participants. The study started on 2023-09-14. Estimated completion is 2028-02.
What conditions does trial NCT06066645 study?
This clinical trial studies the following conditions: Glaucoma Open-Angle.
What interventions are being tested in trial NCT06066645?
The interventions under investigation include: Travoprost Intraocular Implant (DRUG), Sham procedure 1 (OTHER), iStent infinite (DEVICE), Sham procedure 2 (OTHER).
Who is sponsoring clinical trial NCT06066645?
This trial is sponsored by Glaukos Corporation, which has 33 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06066645 being conducted?
This trial has 1 study location across Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma Open-Angle
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.
RECRUITING · Phase 3
-
Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%
COMPLETED · Phase 3
-
A 6-Week Safety and Efficacy Study of Travatan Compared to Xalcom in Subjects With Open-Angle Glaucoma(OAG) or Ocular Hypertension(OHT)
COMPLETED · Phase 3
-
Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension
COMPLETED · Phase 3
-
24-hour Wear Performance and Safety Study of Smartlens miLens Contact Lens for IOP Monitoring
RECRUITING
-
Electrical Stimulation for Vision Neuroenhancement in Glaucoma
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.